AstraZeneca, Breast Cancer
AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the ...
President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...
Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...
DAVOS: Prime Minister Datuk Seri Anwar Ibrahim held high-level meetings with business leaders from six multinational ...
AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback